Spirobarbital

Spirobarbital
Clinical data
Other names	5-spiro-(2'-ethyl-3'-5'-dimethyl-cyclopentyl)barbituric acid
ATC code	none;
Identifiers
	IUPAC name 1-ethyl-2,4-dimethyl-7,9-diazaspiro[4.5]decane-6,8,10-trione;
CAS Number	72035-36-0 ; Sodium salt: 12262-77-0 ;
UNII	LR477QH2IL; Sodium salt: 4NGD254IO1 ;
CompTox Dashboard (EPA)	DTXSID601027534 ;
Chemical and physical data
Formula	C12H18N2O3
Molar mass	238.287 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2NC(=O)NC(=O)C12C(CC)C(C)CC1C;
	(verify)

Spirobarbital is a barbiturate derivative developed by Eli Lilly in the 1940s.^[1] It has hypnotic and sedative effects, and has a moderate potential for abuse.^[2]

References

^ US 2561688, Doran WJ, Van Heyningen EM, "Spirobarbituric Acids", issued 24 July 1951, assigned to Eli Lilly and Company
^ Isbell H, Chruściel TL (1970). "Dependence liability of "non-narcotic" drugs". Bulletin of the World Health Organization. 43 (Supplement): 5–104. PMID 20718122.

This sedative-related article is a stub. You can help Wikipedia by expanding it.